Form 4: Capricor Therapeutics CFO Trades Shares

Capricor Therapeutics' Chief Financial Officer, Anthony Bergmann, reported transactions involving the purchase and sale of company common stock and stock options.

Summary

• Anthony Bergmann, Chief Financial Officer of Capricor Therapeutics, Inc., engaged in several transactions on June 22, 2026, and June 24, 2026.
• On June 22, 2026, Bergmann purchased 500 shares of common stock at $3.18 per share and sold 500 shares at $30 per share.
• On June 24, 2026, Bergmann purchased an additional 400 shares of common stock at $3.18 per share and sold 400 shares at $30 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted in December 2025.
• Following these transactions, Bergmann beneficially owns 11,223 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While the 10b5-1 plan indicates structured trading, the significant sale of shares at a much higher price than the purchase price warrants attention.

Positives

• The CFO's purchase of shares at a lower price ($3.18) could indicate a belief in the stock's future appreciation.
• The execution of trades under a 10b5-1 plan suggests pre-planned, systematic trading activity rather than opportunistic insider trading.

Negatives

• A significant number of shares (900 in total) were sold at a much higher price ($30) compared to the purchase price.
• The sale of shares, even under a 10b5-1 plan, represents a reduction in the CFO's direct beneficial ownership.

Risks

• The sale of a substantial number of shares by a key executive could be interpreted negatively by the market, potentially impacting share price.
• The significant difference between the purchase price and sale price might suggest the CFO is taking advantage of a price discrepancy or has concerns about future price movements.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the purchase of shares at $3.18 by the CFO, alongside sales at $30, could imply a mixed outlook or a strategy to diversify holdings while retaining some exposure.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• Shares vested 1/48th on the first day of each month commencing February 1, 2022.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions. The specific details of the purchase and sale prices, and the execution under a 10b5-1 plan, are critical for investors to interpret the CFO's sentiment towards Capricor Therapeutics' stock.

Stakeholder Impact

• Shareholders may view the sale of shares by the CFO with caution, potentially leading to short-term price pressure.
• Employees with stock options may be influenced by the executive's trading activity, though the 10b5-1 plan provides a structured approach.

Next Steps

• Monitor future Form 4 filings from Capricor Therapeutics' management for any further transactions.
• Observe the market reaction to these reported transactions.

Key Dates

Recommendation

The filing details routine insider transactions under a 10b5-1 plan. While the sale of shares by the CFO at a significant profit is noted, the structured nature of the trade and the simultaneous purchase suggest a balanced approach rather than a strong signal of impending decline or growth. Therefore, a 'hold' recommendation is appropriate pending further company news.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Transaction, Capricor Therapeutics, CAPR, Anthony Bergmann, CFO, Common Stock, Stock Options, 10b5-1 Plan